Cediranib‡ blocks VEGFR-3 activity and inhibits lymphangiogenesis.Anti-VEGFR-3 antibody prevented tumor lymphangiogenesis with no effect on preexisting vessels. This evidence concerns the gene FLT4 and neoplasm.